The compound showed a significant increase in cytotoxicity of PBMCs against both human cancer cell lines: lymphoblasts K562: chronic myelogenous leukemia cell lines and MEC1: B-chronic lymphocytic leukemia cell lineThe compound also had better pharmacokinetic properties than MDP - better adjuvant properties and lower pyrogenicity.In vitro: HEK-Blue NOD2 cells from human embryonic kidney cells HEK293In vivo: NIH/OlaHsd mice. This evidence concerns the gene NOD2 and chronic myelogenous leukemia, BCR-ABL1 positive.